Clinical Trial 21158

• Overview

  Study Title:

  A Phase II Study of PCSK9 Inhibitor Alirocumab and PD-1 Inhibitor Cemiplimab in Patients with Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung Cancer

• Treatments

  Therapies:

  Immunotherapy

  Medications:

  Alirocumab (); Cemiplimab (); REGN2810 (Cemiplimab)

If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.